Home > Browse Issues > Vol.37 No.10
The Progress of IL-13 Receptor Mediated Fusion Protein in Tumor-targeted Therapy
Xiong Shaoheng1,2, Xiong Lixia1*
1Department of Pathophysiology, Basic Medical College, Nanchang University, Nanchang 330036, China;2Department of the Second Clinical Medicine, Nanchang University, Nanchang 330036, China
Abstract: Malignant tumors is one of the most important causes of human death in the world. At present， there are three main kinds of cancer therapy: neoplasia， radiation and chemotherapy. With the development of molecular biology and pathophysiology， tumor-targeted therapy is gradually being recognized. IL-13Rα2 is highly expressed in the tumor cells， but not or low expression in normal cells. It is valuable to use IL-13Rα2 mediated fusion protein targeting tumor and to provide theoretical basis for further clinical use. In this review， we summarize the expression mechanism (especially in cancer cells) of IL-13 receptors stimulated by the IL-13， and discuss development of targeting therapies by recombinant immunotoxins designed to target these receptors.
CN
EN